Details

Autor(en) / Beteiligte

• Gnant, Michael
• Mlineritsch, Brigitte
• Schippinger, Walter
• Luschin-Ebengreuth, Gero
• Pöstlberger, Sabine
• Menzel, Christian
• Jakesz, Raimund
• Seifert, Michael
• Hubalek, Michael
• Bjelic-Radisic, Vesna
• Samonigg, Hellmut
• Tausch, Christoph
• Eidtmann, Holger
• Steger, Günther
• Kwasny, Werner
• Dubsky, Peter
• Fridrik, Michael
• Fitzal, Florian
• Stierer, Michael
• Rücklinger, Ernst
• Greil, Richard

Titel

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

Ist Teil von

• The New England journal of medicine, 2009-02, Vol.360 (7), p.679-691

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2009

Quelle

MEDLINE

Beschreibungen/Notizen

• This large trial tested the effect of adding zoledronic acid to adjuvant endocrine treatment (goserelin plus tamoxifen or anastrozole) in premenopausal women with early-stage breast cancer. The results show that adding zoledronic acid to adjuvant endocrine therapy prolongs disease-free survival in these patients without adding substantially to the burden of adverse events. These results show that adding zoledronic acid to adjuvant endocrine therapy prolongs disease-free survival in premenopausal women with early-stage breast cancer. The optimal management of endocrine-responsive early breast cancer in premenopausal women remains controversial. Although aromatase inhibitors have shown benefits beyond those of tamoxifen in postmenopausal women, 1 – 6 their benefits in premenopausal women, among whom endocrine-responsive disease accounts for 62% of early breast cancers, are unknown. 7 The combination of ovarian suppression with the use of gonadotropin-releasing hormone analogues and tamoxifen is a standard of care for premenopausal women because it is at least as effective as established cytotoxic chemotherapy regimens and is better tolerated than chemotherapy. 8 – 12 In a study involving premenopausal women with advanced breast cancer, ovarian suppression combined with . . .